Published in Pharm Res on April 26, 2007
Measurement of Plasma and Intracellular Concentrations of Raltegravir | NCT01214486
Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 2.25
Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc (2010) 2.18
Appropriate calibration curve fitting in ligand binding assays. AAPS J (2007) 2.08
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses (2012) 1.89
Key elements of bioanalytical method validation for small molecules. AAPS J (2007) 1.84
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother (2009) 1.79
Confirmatory reanalysis of incurred bioanalytical samples. AAPS J (2007) 1.62
Stable-isotope dilution LC–MS for quantitative biomarker analysis. Bioanalysis (2010) 1.56
Relative quantification of serum proteins from pancreatic ductal adenocarcinoma patients by stable isotope dilution liquid chromatography-mass spectrometry. J Proteome Res (2012) 1.47
Nonclinical dose formulation analysis method validation and sample analysis. AAPS J (2010) 1.45
Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2011) 1.18
Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. Antimicrob Agents Chemother (2010) 1.11
Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. J Pharm Biomed Anal (2013) 1.11
Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. Br J Cancer (2010) 1.08
Residual behavior of quizalofop ethyl on onion (Allium cepa L.). Environ Monit Assess (2012) 1.06
Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis (2012) 1.04
Rapid, simultaneous quantitation of mono and dioxygenated metabolites of arachidonic acid in human CSF and rat brain. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.01
Workshop report: Crystal City V--quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidance. AAPS J (2014) 0.99
Nicotine exposure and metabolizer phenotypes from analysis of urinary nicotine and its 15 metabolites by LC-MS. Bioanalysis (2011) 0.97
A sensitive and specific method for measurement of multiple retinoids in human serum with UHPLC-MS/MS. J Lipid Res (2011) 0.96
Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Invest New Drugs (2010) 0.93
Determination of carryover and contamination for mass spectrometry-based chromatographic assays. AAPS J (2007) 0.91
A simple LC-MS/MS method for determination of kynurenine and tryptophan concentrations in human plasma from HIV-infected patients. Bioanalysis (2013) 0.91
Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methods. Steroids (2008) 0.91
Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology (Berl) (2015) 0.91
Development and validation of sensitive LC-MS/MS assays for quantification of HP-β-CD in human plasma and CSF. J Lipid Res (2014) 0.90
Isoprenoid quantitation in human brain tissue: a validated HPLC-fluorescence detection method for endogenous farnesyl- (FPP) and geranylgeranylpyrophosphate (GGPP). Anal Bioanal Chem (2008) 0.89
"Fit-for-purpose" method validation and application of a biomarker (C-terminal telopeptides of type 1 collagen) in denosumab clinical studies. AAPS J (2009) 0.88
Measurement of intracellular ribavirin mono-, di- and triphosphate using solid phase extraction and LC-MS/MS quantification. J Chromatogr B Analyt Technol Biomed Life Sci (2014) 0.88
Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.88
Analytical validation of accelerator mass spectrometry for pharmaceutical development. Bioanalysis (2010) 0.86
A novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell lines. MAbs (2012) 0.85
Estimation of the stability of parathyroid hormone when stored at -80 degrees C for a long period. Clin J Am Soc Nephrol (2009) 0.85
Ligand binding assays in the 21st Century laboratory: platforms. AAPS J (2012) 0.85
Specificity and accuracy data for ligand-binding assays for macromolecules should be interpreted with caution. AAPS J (2008) 0.85
Quantification of the anti-influenza drug zanamivir in plasma using high-throughput HILIC-MS/MS. Bioanalysis (2011) 0.85
Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir. Antimicrob Agents Chemother (2013) 0.84
Simultaneous quantitative determination of bupropion and its three major metabolites in human umbilical cord plasma and placental tissue using high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal (2012) 0.84
Use of pharmacokinetic data below lower limit of quantitation values. Pharm Res (2012) 0.84
Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection. Antimicrob Agents Chemother (2015) 0.83
Statistical considerations for assessment of bioanalytical incurred sample reproducibility. AAPS J (2009) 0.83
Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization Team. AAPS J (2014) 0.83
Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories. Clin Vaccine Immunol (2016) 0.82
Biological Matrix Effects in Quantitative Tandem Mass Spectrometry-Based Analytical Methods: Advancing Biomonitoring. Crit Rev Anal Chem (2016) 0.82
Quantification of artemisinin in human plasma using liquid chromatography coupled to tandem mass spectrometry. J Pharm Biomed Anal (2008) 0.82
Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs. MAbs (2014) 0.82
Exposure to Nicotine and Selected Toxicants in Cigarette Smokers Who Switched to Electronic Cigarettes: A Longitudinal Within-Subjects Observational Study. Nicotine Tob Res (2016) 0.81
Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells. BMC Cancer (2014) 0.81
Development and advanced validation of an optimized method for the quantitation of Aβ42 in human cerebrospinal fluid. AAPS J (2012) 0.81
A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. AAPS J (2014) 0.81
Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther (2015) 0.81
Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasma. Biomed Chromatogr (2011) 0.81
A peptide-based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-erythrocyte malaria vaccines. Clin Vaccine Immunol (2011) 0.81
Multiplexed peptide analysis for kinetic measurements of major human apolipoproteins by LC/MS/MS. J Lipid Res (2016) 0.81
Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist. J Transl Med (2008) 0.80
Assay formats: Recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team. AAPS J (2013) 0.80
A validated LC-MS/MS assay for quantification of 24(S)-hydroxycholesterol in plasma and cerebrospinal fluid. J Lipid Res (2015) 0.79
Development and validation of LC-MS/MS method for determination of very long acyl chain (C22:0 and C24:0) ceramides in human plasma. Anal Bioanal Chem (2013) 0.79
Rapid and simultaneous quantitation of prostanoids by UPLC-MS/MS in rat brain. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.79
A liquid chromatography method with single quadrupole mass spectrometry for quantitative determination of indomethacin in maternal plasma and urine of pregnant patients. J Pharm Biomed Anal (2013) 0.78
Largazole pharmacokinetics in rats by LC-MS/MS. Mar Drugs (2014) 0.78
Repeat analysis and incurred sample reanalysis: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team. AAPS J (2014) 0.78
Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.78
Recommendations and best practices for reference standards and reagents used in bioanalytical method validation. AAPS J (2014) 0.78
Procedural elements involved in maintaining bioanalytical data integrity for good laboratory practices studies and regulated clinical studies. AAPS J (2007) 0.77
Disulfiram metabolite S-methyl-N,N-diethylthiocarbamate quantitation in human plasma with reverse phase ultra performance liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.77
Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum. MAbs (2014) 0.77
Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome. Br J Clin Pharmacol (2015) 0.77
Insights on antioxidant assays for biological samples based on the reduction of copper complexes-the importance of analytical conditions. Int J Mol Sci (2014) 0.76
Validation of the rapid fluorescent focus inhibition test for rabies virus-neutralizing antibodies in clinical samples. Antimicrob Agents Chemother (2012) 0.76
Simultaneous multi-analyte urinary protein assay for bladder cancer detection. BMC Biotechnol (2014) 0.76
Validation of an LC/MS method for the determination of gemfibrozil in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr (2010) 0.76
Data quality in drug discovery: the role of analytical performance in ligand binding assays. J Comput Aided Mol Des (2015) 0.76
Skin permeability and pharmacokinetics of diclofenac epolamine administered by dermal patch in Yorkshire-Landrace pigs. J Pain Res (2012) 0.75
Paracetamol as a Post Prandial Marker for Gastric Emptying, A Food-Drug Interaction on Absorption. PLoS One (2015) 0.75
Detection of β-methylphenethylamine, a novel doping substance, by means of UPLC/MS/MS. Anal Bioanal Chem (2014) 0.75
Simultaneous Determination of Black Tea-Derived Catechins and Theaflavins in Tissues of Tea Consuming Animals Using Ultra-Performance Liquid-Chromatography Tandem Mass Spectrometry. PLoS One (2016) 0.75
Utilizing Internal Standard Responses to Assess Risk on Reporting Bioanalytical Results from Hemolyzed Samples. AAPS J (2015) 0.75
Systemic absorption of rifamycin SV MMX administered as modified-release tablets in healthy volunteers. Antimicrob Agents Chemother (2011) 0.75
Calibrant-Free Analyte Quantitation Via a Variable Velocity Flow Cell. Anal Chem (2016) 0.75
Optimization and Application of Direct Infusion Nanoelectrospray HRMS Method for Large-Scale Urinary Metabolic Phenotyping in Molecular Epidemiology. J Proteome Res (2017) 0.75
Trouble shooting during bioanalytical estimation of drug and metabolites using lc-ms/ms: a review. J Adv Pharm Technol Res (2010) 0.75
Absence of QTc Prolongation with Domperidone: A Randomized, Double-Blind, Placebo- and Positive-Controlled Thorough QT/QTc Study in Healthy Volunteers. Clin Pharmacol Drug Dev (2014) 0.75
Analysis of imprecision in incurred sample reanalysis for small molecules. AAPS J (2014) 0.75
The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation. J Biol Chem (2015) 0.75
Quantification of Synthetic Cathinones in Rat Brain Using HILIC-ESI-MS/MS. J Anal Toxicol (2016) 0.75
Development and Validation of a LC-MS/MS Method for the Simultaneous Estimation of Amlodipine and Valsartan in Human Plasma: Application to a Bioequivalence Study. Sci Pharm (2014) 0.75
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. Br J Cancer (2017) 0.75
Quantitative Analysis of Thyroid Hormone Metabolites in Cell Culture Samples Using LC-MS/MS. Eur Thyroid J (2015) 0.75
Simultaneous determination of rosuvastatin and amlodipine in human plasma using tandem mass spectrometry: Application to disposition kinetics. J Adv Res (2014) 0.75
Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects. Eur J Clin Pharmacol (2012) 0.75
Tear Film Steroid Profiling in Dry Eye Disease by Liquid Chromatography Tandem Mass Spectrometry. Int J Mol Sci (2017) 0.75
Biomarkers of Exposure to New and Emerging Tobacco and Nicotine Delivery Products. Am J Physiol Lung Cell Mol Physiol (2017) 0.75
Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res (2003) 4.54
Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res (2006) 2.96
Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain (2008) 2.91
Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res (2006) 2.65
Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm (2004) 2.63
Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist (2009) 2.37
Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci (2009) 2.36
FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech (2003) 2.03
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res (2008) 1.82
Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res (2002) 1.74
The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res (2008) 1.57
Aortic arch origin of the left external carotid artery and type II proatlantal fetal anastomosis. AJNR Am J Neuroradiol (2003) 1.38
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res (2005) 1.36
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res (2003) 1.29
Platelets are essential for leukocyte recruitment in allergic inflammation. J Allergy Clin Immunol (2003) 1.26
2011 White paper on recent issues in bioanalysis and regulatory findings from audits and inspections. Bioanalysis (2011) 1.12
Toward global standards for comparator pharmaceutical products: case studies of amoxicillin, metronidazole, and zidovudine in the Americas. AAPS J (2012) 1.12
The combination of exposure-response and case-control analyses in regulatory decision making. J Clin Pharmacol (2013) 1.11
Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS. J Pharmacol Toxicol Methods (2009) 1.11
Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J (2010) 1.10
Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm Res (2005) 1.09
2012 white paper on recent issues in bioanalysis and alignment of multiple guidelines. Bioanalysis (2012) 1.09
Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res (2008) 1.08
Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther (2010) 1.04
Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond. AAPS J (2008) 1.01
AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol (2007) 1.01
Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies. Clin Cancer Res (2008) 1.00
Workshop report: Crystal City V--quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidance. AAPS J (2014) 0.99
Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab Dispos (2004) 0.98
Assessment of dermatopharmacokinetic approach in the bioequivalence determination of topical tretinoin gel products. J Am Acad Dermatol (2003) 0.98
Building the Global Bioanalysis Consortium - working towards a functional globally acceptable and harmonized guideline on bioanalytical method validation. Bioanalysis (2010) 0.98
Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity. J Med Chem (2008) 0.96
Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis (2013) 0.96
Conference report: Bio-International 2005. J Pharm Sci (2007) 0.95
Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy. Oncologist (2008) 0.93
Serum hepcidin but not prohepcidin may be an effective marker for anemia of inflammation (AI). Blood Cells Mol Dis (2010) 0.93
Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol (2003) 0.91
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res (2012) 0.91
Qualification of analytical instruments for use in the pharmaceutical industry: a scientific approach. AAPS PharmSciTech (2004) 0.91
Pharmacokinetics of etoricoxib in patients with hepatic impairment. J Clin Pharmacol (2003) 0.89
Biowaiver monographs for immediate release solid oral dosage forms: metronidazole. J Pharm Sci (2011) 0.89
Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline. J Med Chem (2009) 0.87
Validation of USP apparatus 4 method for microsphere in vitro release testing using Risperdal Consta. Int J Pharm (2011) 0.86
Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified-release products: workshop summary report. Eur J Pharm Sci (2010) 0.86
Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report. Eur J Pharm Sci (2011) 0.86
Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop. AAPS J (2011) 0.85
Bioequivalence of topical formulations in humans: evaluation by dermal microdialysis sampling and the dermatopharmacokinetic method. J Invest Dermatol (2006) 0.85
Direct quantitative analysis of a 20 kDa PEGylated human calcitonin gene peptide antagonist in cynomolgus monkey serum using in-source CID and UPLC-MS/MS. J Am Soc Mass Spectrom (2011) 0.85
A standardized mini paddle apparatus as an alternative to the standard paddle. AAPS PharmSciTech (2008) 0.85
Understanding and mitigating impact of immunogenicity on pharmacokinetic assays. Bioanalysis (2011) 0.84
Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report. AAPS J (2011) 0.84
Current challenges in bioequivalence, quality, and novel assessment technologies for topical products. Pharm Res (2014) 0.83
2010 white paper on recent issues in regulated bioanalysis & global harmonization of bioanalytical guidance. Bioanalysis (2010) 0.83
Biowaiver monographs for immediate-release solid oral dosage forms: primaquine phosphate. J Pharm Sci (2011) 0.83
Comparison of skin stripping, in vitro release, and skin blanching response methods to measure dose response and similarity of triamcinolone acetonide cream strengths from two manufactured sources. J Pharm Sci (2002) 0.82
Characterization and development of a Luminex(®)-based assay for the detection of human IL-23. Bioanalysis (2010) 0.82
Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology (Williston Park) (2006) 0.82
Immunoassay-based measurement of clinical biomarkers for monitoring changes in nasal cavity. J Pharm Biomed Anal (2009) 0.81
Determination of the formation of the stratum corneum reservoir for two different corticosteroid formulations using tape stripping combined with UV/VIS spectroscopy. J Dtsch Dermatol Ges (2004) 0.81
Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies. Anal Bioanal Chem (2011) 0.81
Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue. Arch Pathol Lab Med (2016) 0.81
Different pharmaceutical products need similar terminology. AAPS J (2013) 0.81
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity). Bioanalysis (2014) 0.80
From drug delivery systems to drug release, dissolution, IVIVC, BCS, BDDCS, bioequivalence and biowaivers. Pharm Res (2010) 0.80
FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech (2011) 0.80
Biorelevant in vitro performance testing of orally administered dosage forms-workshop report. Pharm Res (2014) 0.80
How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider. AAPS J (2013) 0.80
Improved therapeutic entities derived from known generics as an unexplored source of innovative drug products. Eur J Pharm Sci (2011) 0.80
An ultra-sensitive clinical biomarker assay: quantitation of thymus and activation-regulated chemokine in human plasma. Bioanalysis (2014) 0.80
Evaluation of a quantitative product-enhanced reverse transcriptase assay to monitor retrovirus in mAb cell-culture. Biologicals (2002) 0.79
Biowaiver monographs for immediate-release solid oral dosage forms: ketoprofen. J Pharm Sci (2012) 0.79
Bioanalytical method validation: concepts, expectations and challenges in small molecule and macromolecule--a report of PITTCON 2013 symposium. AAPS J (2014) 0.79
FIP position paper on qualification of paddle and basket dissolution apparatus. AAPS PharmSciTech (2009) 0.78
Biowaiver monographs for immediate release solid oral dosage forms: efavirenz. J Pharm Sci (2012) 0.78
Impact of cell culture process changes on endogenous retrovirus expression. Biotechnol Bioeng (2002) 0.78
2013 White Paper on recent issues in bioanalysis: 'hybrid'--the best of LBA and LCMS. Bioanalysis (2013) 0.78
Practical guidance for implementing predictive biomarkers into early phase clinical studies. Biomed Res Int (2013) 0.77
Bioavailability and bioequivalence: focus on physiological factors and variability. Pharm Res (2008) 0.77
Development and validation of an ultra-sensitive method for the measurement of plasma renin activity in human plasma via LC-MS/MS. Bioanalysis (2012) 0.77
The effect of irritant dermatitis on cutaneous bioavailability of a metronidazole formulation, investigated by microdialysis and dermatopharmacokinetic method. Contact Dermatitis (2008) 0.77
Impact of the pharmaceutical sciences on health care: a reflection over the past 50 years. J Pharm Sci (2012) 0.77
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 - hybrid LBA/LCMS, ELN & regulatory agencies' input). Bioanalysis (2014) 0.76
Best practices for the development, scale-up, and post-approval change control of IR and MR dosage forms in the current quality-by-design paradigm. AAPS PharmSciTech (2014) 0.76
Biowaiver monographs for immediate release solid oral dosage forms: amodiaquine hydrochloride. J Pharm Sci (2012) 0.76
Workshop Report: AAPS Workshop on Method Development, Validation, and Troubleshooting of Ligand-Binding Assays in the Regulated Environment. AAPS J (2015) 0.75
Change in criteria for USP dissolution performance verification tests. AAPS PharmSciTech (2009) 0.75
Development and validation of a clinical trial patient stratification assay that interrogates 27 mutation sites in MAPK pathway genes. PLoS One (2013) 0.75
Technical aspects of inductively coupled plasma bioanalysis techniques. Bioanalysis (2013) 0.75
Novel metrics to compare dissolution profiles. Pharm Dev Technol (2002) 0.75